ALUPENT
LOE ApproachingNDAINHALATIONSOLUTIONPriority Review
Approved
Sep 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is an inhalation solution small-molecule bronchodilator approved in 1980 for respiratory indications. The generic name and specific mechanism of action are not publicly detailed in available sources, but the product is a established maintenance therapy for obstructive airway disease.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating a contracting team and shift toward lifecycle management and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ALUPENT offers limited growth opportunity due to LOE approaching; roles are primarily focused on defending market share, managing generic transition, and optimizing profitability. Career development here centers on lifecycle management expertise rather than product innovation.
Brand ManagerProduct Manager
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.